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Introduction 
While  smart  multifunctional  nanomedicines  and 
theranostics  are  becoming  robust  seamless  tools  for 
simultaneous imaging and therapy of cancer, for their 
effective  clinical  implementations  we  need  a)  to 
advance  technologies  for  specific  targeting  of  cancer 
cells,  b)  to  improve  imaging/sensing  methods,  c)  to 
develop biocompatible long circulating bioshuttles for 
simultaneous  delivery  of  targeting  moiety,  imaging 
agent  and  therapy,  and  d)  to  track  and  control 
cancerous single cells/bioconvoys to avoid distribution 
of  oncogenic  messages,  the  so  called  metastasis.
1  Of 
various  advancements  holding  great  promise  for 
improving  the  sensing/imagining  cancerous  cells, 
superparamagnetic/magnetic  NPs  as  effective  contrast 
agents,
2-4 appear to meet such criteria.  
MNPs  have  been  used  as  nanocarriers  for  specific 
delivery of chemotherapy agents.
5-7 Possessing unique 
properties,  they  can  be  conjugated  with  different 
moieties such as targeting and therapeutics agents. Also 
MNPs  have  been  used  for  various  purposes  such  as 
magnetic  bio  separation,  cell  labeling,  hyperthermia 
treatment  of  solid  tumors  and  contrast  agents  for 
magnetic resonance imaging (MRI).
8-10 
In  biological  micro-compartments  such  as  tumor 
microenvironment,  the  surface-modified  MNPs  ensue 
to display excellent dispersion characteristics, while the 
unmodified  MNPs  have  high  propensity  to  form 
agglomerated macrostructures that can be taken up by 
mononuclear  phagocyte  system  (MPS)  resulting  in 
significant  loss  of  MNPs  in  blood  circulation.
11,12 
Surface  modification  of  MNPs  with  biocompatible 
polymers  (e.g.,  polyethylene  glycol  (PEG))  can 
markedly  protect  them  against  immune  system 
clearance  providing  longer  circulation  in  blood. 
Further, surface modifications of MNPs were shown to 
improve their stability, biocompatibility, drug loading 
potential,  and  interaction  capability  with  the  target 
cells/tissues.
13,14  MNPs  can  become  stealth  through 
PEGylation,  at  which  they  can  circumvent  the 
opsonization.
15,16  PEG  grafts  also  provide  further 
conjugation  potential  with  homing  devices  while 
keeping  them  longer  in  the  blood  stream  and  thus 
providing higher accumulation in the target sites.
11 
Targeted  MNPs  are  often  armed  with  moieties  that 
enable them to detect the disease specific markers such 
as  cancer  marker  molecules  (CMMs),  resulting  in 
simultaneous targeted therapy and imaging. Of CMMs, 
folate  receptors  were  shown  to  be  upregulated  in 
various tumors
17 thus can be targeted by folic acid (FA) 
which  displays  extremely  high  affinity  to  the  folate 
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decomposition  of  Fe(acac) 3.  Then,  magnetic  nanoparticles  (MNPs)  modified  by 
dopamine-poly  ethylene  glycol  (PEG) -NH2;  finally,  half  equivalent  fluorescein 
isothiocyanate (FITC) and half equivalent folic acid were conjugated to one equivalent 
of it. The presence of Fe 3O4-DPA-PEG-FA/FITC in the folate receptor (FR) positive 
MCF-7  cells  was  determined  via  fluorescent  microscopy  to  monitor  the  cellular 
interaction of MNPs. Results: FT-IR spectra of final compound confirmed existence of 
fluorescein on folic acid grafted MNPs. The Fe3O4-DPA-PEG-FA/FITC NPs, which 
displayed a size rang about 30-35 nm using scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM),  were  able  to  actively  recognize  the  FR-
positive MCF-7 cells, but not the FR-negative A549 cells. Conclusion: The uniform 
nano-sized Fe3O4-DPA-PEG-FA/FITC NPs displayed great potential as theranostics 
and can be used for targeted imaging of various tumors that overexpress FR.  
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receptors. Previously, we have capitalized on synthesis 
of  targeted  fluorophoromagnetic  nanoparticles 
conjugated with mitoxantrone (MTX).
18 To pursue the 
internalization of the FA conjugated MNPs by the FR 
positive breast cancer MCF-7cells, in the current study, 
we exploited FA conjugated PEGylated MNPs labeled 
with Fluorescein isothiocyanate (FITC). Conjugation of 
FA to the surface of MNPs can combine the passive 
targeting  potential  of  MNPs  with  active  targeting 
capabilities,  resulting  in  enhanced  permeation  and 
retention (EPR) effects together with increased specific 
targeting of the tumor cells.
16,19 FITC has widely been 
used  for  optical  detection  of  NPs  by  fluorescence 
microscopy and flow cytometry, so we functionalized 
MNPs with an isothiocyanate through reactive group (-
N=C=S) that can react with terminal amines.
20 
 
Materials and Methods 
 Iron (III) acetylacetonate (Fe(acac)3) and benzyl ether 
were  purchased  from  Merck  chemical  company 
(Hohenbrunn,  Germany).  Poly  Ethylene  Glycol 
(PEG2000),  triethylamine,  N,N,  dicyclohexyl-
carbodiimide  (DCC),  and  N-hydroxysuccinimide 
(NHS)  were  purchased  from  Merck  Chemical 
Company  (Darmstadt,  Germany).  Oleylamine, 
bromoacetyl  chloride,  fluorescein  isothiocyanate 
isomer  Ι  (FITC),  RPMI  1640  media,  MTT  and 
dopamine hydrobromide  (DPA)  were  purchased  from 
Sigma-Aldrich Company (Steinheim, Germany). Folic 
acid  was  purchased  from  Acros  Organics  Company 
(New  Jersey,  USA).  N-tert-Butoxycarbonyl-1,  2-
ethylenediamine  was  purchased  from  Alfa  Aesar 
Company  (Lancashire,  UK).  Penicillin-Streptomycin 
and  Fetal  Bovine  Serum  were  purchased  from 
Invitrogen  (Paisley,  UK).  MCF-7  cell  lines  were 
purchased  from  Pastor  Cell  bank  (Iran).  All  other 
reagents  and  solvents  were  common  analytical  grade 
and pure.  
 
Preparation of Fe3O4 Nanoparticles 
Fe(acac)3(2.12 g, 6.0 mmol) was dissolved in a mixture 
of benzyl ether and oleylamine (30 mL: 30 mL) and 
were stirred by magnetic stirrer.
21-23 The solution was 
dehydrated  at  120  °C  for  1h  using  Dean-Stark 
apparatus  and  under  flow  of  argon.  After  1  h, 
temperature was raised quickly to 270 °C for 2 h under 
argon. The reaction mixture was cooled down to room 
temperature and then ethanol (80 mL) was added to the 
dark brown mixture and precipitated with centrifuge at 
5000 rpm. The product was re-dispersed in 30 mL n-
hexane and stored at 4 °C.
18 Figure 1 Step 1 represents 
this process. The yield was 1.8 g, i.e. 84.9%. 
 
Synthesis of O-(2
'-Boc-Imino-Ethylene-Imino)-O
'-(2-
Dopamineacetyl) Polyethylene Glycol (DPA-PEG-NHBoc) 
For  synthesise  of  DPA-PEG-NHBoc,  we  conducted 
three main steps as described previously.
22 
First, polyethylene glycol (PEG2000) (10.0 g, 5.0 mmol), 
bromoacethyl  chloride  (1.75  mL,  20.0  mmol)  and 
triethylamine (2.8 mL, 20 mmol) were dissolved in 20 
mL  dichloromethane.  H-NMR  result  was:   H  (400 
MHz; CDCl3) 3.55-3.70 (234 H, -O-CH2-CH2-O-), 4.07 
(4H, s, –CH2-Br) and 4.32 (4H, t, –CH2-COO-).  
Second,  BBrAC-PEG  (7.50  g,  3.345  mmol)  was 
dissolved in 250 mL dichloromethane, then dopamine 
hydrobromide  (0.817  g,  3.487  mmol),  KI  (0.277  g, 
1.6725mmol) and K2CO3 (1.615g, 11.707mmol) were 
added  to  the  solution.  H-NMR  result  was:   H(400 
MHz; CDCl3) 2.69 (2H, t, -CH2-CH2N-), 2.90 (2H, t, –
Ph-CH2-CH2-),  3.5-3.7  (234  H,  -O-CH2-CH2-O-), 
4.0979 (2H, s, –CH2-Br), 4.245 (4H, t, –CH2-COO-), 
6.54 (1H, d, Ph) and 6.74 (2H, m, Ph).  
Third, DPA-PEG-BrAC (6.00 g, 2.51mmol) and N-tert-
butoxycarbonyl-1,2-ethylenediamine  (0.475g, 
3.012mmol)  were  dissolved  in  dichloromethane  (250 
mL). Then, KI (0.50 g, 3.012mmol) and K2CO3 (1.757 
g, 12.552 mmol) were added. H-NMR result was: 
H(400 MHz; CDCl3) 1.409 (9H, s, t-Bu), 2.66 (2H, t, –
CH2-CH2N-), 2.80 (2H, t, –Ph-CH2-CH2), 2.90 (2H, t, –
CH2-CH2-NHBoc), 3.22 (2H, t, -CH2-NHBoc), 3.5-3.7 
(234 H, -O-CH2-CH2-O-), 4.1 (2H, s, Ph-CH2-CH2-NH-
CH2-  and  2H  of  –CH2-NH-CH2-CH2-  NHBoc),  4.33 
(4H, t, - CH2-COO-), 6.53 (1H, d, Ph) and 6.76 (2H, m, 
Ph).  
 
 
Figure 1. Schematic representation of step-wise synthesis of 
Fe3O4-DPA-PEG-FA/FITC nanoparticles.  
 
All The solutions were stirred overnight under argon at 
room temperature (RT) also the insoluble compounds 
filtered  using  Buchner  vacuum  filtration  funnel.  In 
three steps for purification of the products, the solvent 
(dichloromethane) was removed using a rotary vacuum 
evaporator  (Heidolph,  Schwabach,  Germany)  and  30 
mL diethyl ether was added for precipitation. Diethyl 
ether was removed using a rotary evaporator, and then 
products  were  redissolved  in  water/NaCl  (35%w/v). 
Products were extracted from water by the addition of 
30  mL  dichloromethane  and  re-precipitation  with  30 
mL diethyl ether.  
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DPA-PEG-NHBoc (1.0 g, 0.04 mmol) was dissolved in 
dichloromethane  (20  mL).  The  solution  was  stirred 
using a magnetic stirrer. Then trifluoroacetic acid (1.5 
mL) was added and stirred for 1h at RT. Solvent was 
removed by rotary and product (DPA-PEG-NH2) was 
washed  (3×)  with  dichloromethane.  The  final  brown 
color product was precipitated using diethyl ether.  
 
Preparation of Fe3O4-DPA-PEG-NH2 and Conjugation 
Fe3O4  (0.5  g,  2.16  mmol)  was  dispersed  in 
dichloromethane (50 mL).
22 DPA-PEG-NH2 (2.5 g) was 
added to the solution and stirred overnight under argon 
blanket  at  25  °C.  After  one  night,  solutions  were 
sonicated for 15 min and then, Fe3O4-DPA-PEG-NH2 
was  precipitated  using  hexane  and  gathered  by 
centrifugation  at  4000  rpm.  For  purification  of 
modified  Fe3O4,  the  samples  were  washed  (3×)  with 
dichloromethane/hexane  (1:5)  mixture.  Finally,  the 
solid dark-brown color product was re-dispersed in 20 
mL  ethanol.  Figure  1  schematically  represents  the 
engineering process. 
For  conjugation,  in  the  first  step, 
N,N,dicyclohexylcarbodiimide  (DCC)  (2.95  g,  14.3 
mmol),  folic  acid  (3g,  6.8  mmol)  and  N-
hydroxysuccinimide (NHS) (1.643 g, 14.3 mmol) were 
dissolved  in  dimethylsulfoxide  (DMSO)  (30  mL) 
(2.1:1:2.1mmol).
24  Triethylamine  (1.88  mL,  13.6 
mmol)  was  added  to  the  solution  while  solution  was 
stirred  overnight  at  RT  under  argon  blanket.  Then, 
hexane (40 mL) was added to the flask for precipitation 
and yellow color product was washed with ether (yield 
was 1.66 g, 55.33%).  
In  the  second  step,  modified  Fe3O4-DPA-PEG-NH2 
(1.00  g)  was  dispersed  in  10  mL  DMSO,  and  then 
triethylamine (0.17 mL, 1.248 mmol) was added to the 
solution.
25  FA-NHS  (0.0985  g,  0.156  mmol)  and 
fluorescein  isothiocyanate  (FITC)  (0.0607  g,  0.156 
mmol) were each dissolved in DMSO (5 mL). The two 
solutions were  added to  the reaction  flask  containing 
compound  and  stirred  at  room  temperature  overnight 
under argon blanket. The final product was collected 
with  Invitrogen  bead  separation  system  (DYNAL), 
washed with deionized water (3×) and characterized by 
FT-IR  (Shimadzu  FT-IR-8400S  spectrophotometer, 
Shimadzu Scientific Instruments, Japan).  
Cell Culture  
The FR-positive MCF-7 cell line and the FR-negative 
lung cancer cell line were used for this study. Both cell 
lines  were  cultured  at  a  seeding  density  of  4.0  × 
10
4cells/cm
2 onto the cultivation plates/coverslips using 
normal  culture  medium  (DMEM  supplemented  with 
10% FBS, 100 units/mL penicillin G and 100 μg/mL 
streptomycin). The cultured cells were kept at 37 °C in 
a  humidified  CO2  incubator  during  cultivation  and 
during experiments.  
Fluorescence Microscopy 
For fluorescence microscopy, cells were cultivated as 
described  onto  the  22-mm
2  coverslips.  At  40-50% 
confluency,  they  were  exposed  to  a  designated 
concentration  of  Fe3O4-DPA-PEG-FA/FITC  NPs  (5 
µg/mL) for 1 h at 37 °C in the CO2 incubator. Fixation 
involved washing the cells (3×) with PBS, followed by 
10  min  incubation  with  2%  formaldehyde  in  PBS  at 
room temperature. After washing cells (3×) with PBS, 
they were mounted on slides using mounting medium 
without/with  DAPI  (50  μM,  for  20  min)  for  nuclear 
staining. The prepared samples were examined utilizing 
an Olympus IX81 compound fluorescence microscope 
equipped  with  XM10  monochrome  camera,  Olympus 
optical  Co.,  Ltd.  (Tokyo,  Japan)  as  described 
previously. 
 
Cellular Impacts 
To  pursue  the  cellular  impacts  of  the  targeted 
fluorophoromagnetic  nanoparticles,  MTT  cytotoxicity 
assay  was  used.  The  cultivated  cells,  at  40-50% 
confluency,  were  exposed  to  Fe3O4-DPA-PEG-
FA/FITC NPs (0-5 µg/mL). The media was removed 
and  150  µL  fresh  media  plus  50  µL  MTT  solutions 
(prepared as 2 mg/mL in FBS) were added to each well 
and incubated for 4 h at 37 °C in a CO2 incubator. The 
media was  removed and  the cells  were washed  (3×), 
then  the  formed  formazin  crystals  were  dissolved  by 
adding DMSO (200 µL) and Sorenson’s buffer (25 µL) 
to each well plate. The absorbance was read at 570 nm 
using  a  spectrophotometer  (BioTek  Instruments,  Inc., 
Bad Friedrichshall, Germany). 
 
Results  
Characterization of Fe3O4 Nanoparticles 
The  synthesized  Fe3O4  nanoparticles  at  270°C  by 
thermal  decomposition  reaction  of  Fe  (acac)3 showed 
average size about 7 nm (Figure 1, step 1). For removal 
of  water  from  reaction  environment,  the  reaction 
mixture was performed using Dean-Stark apparatus at 
120 °C. Size of Fe3O4 MNPs was determined using a 
particle  size  analyser  Zetasizer  Nano  ZS  (Malvern 
Instruments, UK). As shown in Figure 2A, the surface 
modification of MNPs with oleylamine layer analysed 
by  FT-IR  spectroscopy  that  revealed  the  main 
absorption peaks for oleylamineare: ν (NH2) 3435 cm
-1, 
νmax/cm
-1 3001(=C-H) and 2954s, 2924s, 2852s (C-H); 
and the explicit absorption peaks related to Fe3O4 are: 
νmax/cm
-1  630,  588,  442(Fe-O).  Figure  2A  shows 
another  important  peak  at  1523  that  represents 
coordinated bond between Fe (III) of Fe3O4 and NH2 of 
oleylamine (Fe-N bond). 
 
Characterization of DPA-PEG-NH2 
For  synthesis  of  DPA-PEG-NH2,  in  the  first  step 
BBrAC-PEG  was  synthesized  by  reacting  excess 
amount  of  bromoacetyl  chloride  with  PEG  in  the 
presence  of  triethylamine  as  a  base.  The  FT-IR 
spectroscopy  (Figure  2)  validated  formation  of  the 
BBrAC-PEG, resulting in νmax/cm
-1 1750 (C=O, PEG-
bromoacetyl),  1100  (C-O-C,  PEG)  and  2880s  (CH2). 
The  peak  at  1750  cm
-1  confirms  existence  of  
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carboxylate  in  structure  of  PEG.  In  the  second  step, 
reaction  of  BBrAC-PEG  with  one  equivalent  of 
dopamine  yielded  DPA-PEG-BrAc.  FT-IR  spectrum 
confirmed  existence  of  phenyl  ring  in  DPA-PEG-
BrAcwith νmax/cm
-1 3100s(=C-H). In the third step, the 
DPA-PEG-BrAc  was  treated  with  N-tert-
butoxycarbonyl-1,2-ethylenediamineto gain DPA-PEG-
NHBoc, in which the boc (N-tert-butoxycarbonyl) was 
removed by trifluoroacetic acid (TFA). The synthesis 
of DPA-PEG-NH2 was also confirmed by H-NMR. 
 
 
Figure 2. FT-IR spectrophotometer of synthesized Fe3O4-DPA-PEG-FA/FITC nanoparticles. A) Fe3O4- MNPs. B) Fe3O4-DPA-PEG-NH2, 
absorption peak in ν (1487 cm-1) is related to NH3
+ available in salt of NH2TFA. C) Fe3O4-DPA-PEG-FA/FITC, the symmetric and 
asymmetric C=S stretching vibrations at 730 and 1417 cm
-1 confirmed the formation of thiourea group in the Fe3O4- DPA-PEG-FA/FITC. 
 
Characterization of Modified Fe3O4 
The  surface  of  Fe3O4  was  modified  with  DPA-PEG-
NH2 using dopamine moiety. Dopamine has been used 
as  an  anchoring  agent  in  DPA-PEG-NH2  that  could 
replace  the  oleylamine  on  surface  of  Fe3O4  MNPs. 
TEM  and  SEM  micrographs  determined  the 
morphology  and  size  of  Fe3O4-DPA-PEG-NH2  with 
diameter  ~13  nm  (data  not  shown).  In  the  FT-IR 
spectrum of the Fe3O4-DPA-PEG-NH2, in addition to 
the peaks related to Fe3O4 and DPA-PEG, absorption 
peak  at  νmax/cm
-11487  cm
-1  is  seen  that  is  related  to 
NH3
+  available  in  salt  of  NH2TFA  at  the  end  of  the  
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structure of the Fe3O4-DPA-PEG-NH2 (Figure 2B). To 
quantify the exact amount of the DPA-PEG-NH2 used 
to  coat  the  Fe3O4  cores,  the  solvent  media  of  the 
supernatant was removed using rotary evaporator and 
the remained DPA-PEG-NH2 was analyzed.  
 
Characterization  of  Fluorophor  Conjugated-Fe3O4 
Magnetic Nanoparticles 
When  half  equivalent  FITC  and  half  equivalent  FA 
were conjugated to one equivalent of Fe3O4-DPA-PEG-
NH2, both moieties (i.e., FA and FITC) were available 
on FA and FITC grafted MNPs. FA was used to target 
the FR, while FITC was used to provide a possibility 
for  fluorescence  microscopy  of  cancer  cells.  FT-IR 
analysis of FA-MNPs-FITC confirmed conjugation of 
FITC onto the MNPs (Figure 2C). The symmetric and 
asymmetric C=S stretching vibrations at 730 and 1417 
cm
-1 confirmed the formation of thiourea group in the 
Fe3O4-MNP-FA/FITC. Furthermore, bond at 3435 cm
-1 
related  to  NH2  stretching  was  detected  on  surface  of 
MNPs. The TEM and SEM determined the morphology 
and  size  (~30  nm)  of  Fe3O4-DPA-PEG-FA/FITC 
(Figure 3).  
 
 
Figure  3.  TEM  (A)  and  SEM  (B)  nano-graph  Fe3O4-DPA-
PEG-FA/FITC  nanoparticles.  TEM:  transmission  electron 
microscopy. SEM: scanning electron microscopy. 
 
Fluorescence Microscopy and Cellular Impacts 
To visualize the cellular interaction of the FR targeted 
fluoromagnetic NPs, the FR-positive MCF-7 cells and 
the  FR-negative  A549  cells  were  exposed  to  Fe3O4-
DPA-PEG-FA/FITC  (5  µg/mL)  for  1  h.  Figure  4 
represents the fluorescence microscopy of the MCF-7 
cells treated with FR targeted fluoromagnetic NPs. We 
witnessed substantial binding and/or internalization of 
the FR targeted fluoromagnetic NPs in the FR-positive 
MCF-7 cells (Figure 4), but not the FR-negative A549 
cells  (data  not  shown),  indicating  the  specificity  of 
these  nanosystems  toward  folate  receptor  expressing 
cells.  
 
 
Figure  4.  Fluorescence  and  light  microscopy  of  the  MCF-7 
cells  treated  with  Fe3O4-DPA-PEG-FA/FITC.  A)  Differential 
interference  contrast  (DIC)  microscopy  image  of  the  MCF-7 
cells. B) Fluorescence microscopy (FM) image of the MCF-7 
cells  treated  with  fluorophore  tagged  nanoparticles  (MNPs-
FA/FITC).C) Superimposed DIC and FM image. 
 
Since these FR targeting fluoromagnetic NPs are used 
for targeted imaging, we aimed to see their nonspecific 
toxicity  using  MTT  assay.  Figure  5  represents  the 
viability  of  the  treated  MCF-7  cells  with  designated 
amount  of  FR  targeting  fluoromagnetic  NPs,  which 
indicate negligible cytotoxicity.  
 
 
Figure  5.  Cellular  impacts  of  Fe3O4-DPA-PEG-FA/FITC  in 
MCF-7 cells.  
 
Discussion 
Given the fact that nanosized macromolecules are often 
prone  to  opsonisation  by  MPS,  the  MNPs  are 
PEGylated  to  become  stealth.  Such  modified  MNPs  
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appear to show markedly long circulation in blood and 
thus high level of extravasation and accumulation in the 
tumor  site.  They  were  seen  as  clustered  inside  the 
various stages of endocytic pathways without damaging 
cellular  organelles  where  endocytosis  mechanism  for 
their  entry  appears  to  be  a  receptor  mediated 
endocytosis,
26 mainly through targeting a CMM such as 
FR. It should be noted that the absorption of folate is 
primarily  mediated  by  a  membrane  transporter  with 
micro-molar  affinities  for  folates,  in  which  the  FRs 
with  nanomolar  affinities  to  folate  are  likely  to 
markedly  modulate  folate  availability  for  these 
transporters  and  functional  isoforms  of  FRs  are 
anchored to the membrane by a glycolipid anchor, the 
glycosylphosphatidylinositol  (GPI)  anchor.
27  Further, 
colocalization  of  folate  and  transferrin  receptors
28 
clearly  indicate  that  the  endocytosis  of  the  targeted 
fluoromagnetic  NPs  is  a  receptor  mediated  process, 
presumably  via  calthrin  coated  pites  and/or 
membranous caveolae. Thus, we aimed to look at the 
internalization of FR targeting fluoromagnetic NPs in 
FR-expressing cells.  
We synthesized Fe3O4 NPs by thermal decomposition 
reaction of Fe(acac)3 and undertook a series of surface 
modification steps to achieve FITC and FA conjugated 
MNPs  (Figures  1-3).  The  synthesized  Fe3O4  NPs 
through  thermal  decomposition  reaction  of  Fe(acac)3 
showed average size about 10 nm, similar to previous 
reports.
22  We  used  the  DPA-PEG-NH2  to coat  the 
Fe3O4  NPs  to  achieve  more  hydrophilic  and  stealth 
MNPs.  Further,  the  DPA-PEG-NH2 modification  can 
provide a versatile platform for further conjugation of 
MNPs with other functional groups.
29 The PEGylated 
MNPs  (Fe3O4-DPA-PEG-NH2)  were  conjugated  with 
FA  and  FITC  to  produce  Fe3O4-DPA-PEG-FA/FITC 
NPs. We used FA to actively target the FR, at which 
these FA armed MNPs can specifically target the FR-
positive breast cancer cells.
30 
Our  fluorescence  microscopy  analysis  resulted  in 
significant uptake of FR targeting fluoromagnetic NPs 
by the FR-positive MCF-7 cells (Figure 4). The time-
dependency of this process indicate the binding of the 
MNPs  to  the  cell  surface  via  folate  receptor  and 
endocytosis via vesicular trafficking. Following cellular 
uptake,  membrane-encapsulated  silicon  particles 
migrated  to  the  perinuclear  region  of  the  cell  by  a 
microtubule-driven mechanism.
31 Based upon our flow 
cytometry analysis, the FR targeting MNPs appeared to 
specifically  quantitatively  (>95%)  detect  the  FR 
expressing  cells,
18  while  no  specific  cytotoxicity  was 
observed  in  the  treated  cells  even  with  high 
concentration  of  FR  targeting  fluoromagnetic  NPs 
(Figure 5). We speculate that they harness the vesicular 
trafficking  pathway(s)  for  internalization,  i.e.  the 
early/late  endosomal  machineries.  Thus,  these 
nanocarriers,  if  used  as  drug  delivery  nanosystem, 
should  be  able  to  escape  from  demise  in  the  late 
endsome/lysosome.  Lysosomes  contain  approximately 
over  40  different  hydrolytic  enzymes  that  mediate 
controlled  intracellular  degradation  of 
macromolecules.
32  Thus,  due  to  uniqueness  of  these 
trafficking machineries (enzyme composition and pH), 
targeted MNPs grafted with cytotoxic agents should be 
engineered in a way to be able to exploit such potential. 
These FR targeting fluoromagnetic NPs, however, prior 
to  transformation  into  clinical  application,  should  be 
fully  characterized  and  tested  in  appropriate  animal 
models.  
 
Conclusion 
The  nano-scaled  targeted  fluoromagnetic  theranostics 
have great potential toward simultaneous imaging and 
therapy. In this work, we have demonstrated successful 
synthesis of folic acid/ fluorescein isothiocyanate-PEG 
conjugated  magnetic  nanoparticles  which  could 
markedly detect the FR expressing cancer cells. Thus, 
we  propose  that  they  can  be  quantitatively  used  for 
specific  MRI-based  imaging  and  therapy  of  various 
cancers.  
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